The prevalence of gastrinomas and the Zollinger-Ellison syndrome is unknown. In order to examine a high risk group of patients, basal and secretin-provoked plasma gastrin levels were determined in 50 consecutive patients, predominantly from the west of Scotland. All had endoscopically proven recurrent peptic ulceration following duodenal ulcer surgery. This resulted in three cases strongly suspected of having a gastrinoma. Further investigations including exploratory laparotomy were unable to demonstrate a gastrinoma in two, but the evidence suggested an occult tumour in one. In this remaining unoperated patient, the serum gastrin returned to normal. The reference range for both basal and secretin stimulated gastrin response and percentage change has been determined in normal control subjects (n=10) and in primary ulcer patients (n=20). It is concluded that in this study, gastrinomas had a less than 2 per cent prevalence in patients presenting with recurrent peptic ulceration. As the diagnosis of a gastrinoma changes the surgical approach, conducting screening tests still seems warranted.
[1]
J. Jansen,et al.
Secretin injection test in the diagnosis of gastrinoma
,
1981
.
[2]
J. Primrose,et al.
Assessment of the secretin provocation test in the diagnosis of gastrinoma
,
1980,
The British journal of surgery.
[3]
L. Way,et al.
The Zollinger‐Ellison Syndrome—23 Years Later
,
1978,
Annals of surgery.
[4]
J. V. van Tongeren,et al.
Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome.
,
1977,
Gut.
[5]
J. Polak,et al.
Antral-gastrin-cell hyperplasia in peptic-ulcer disease.
,
1974,
Lancet.
[6]
J. Isenberg,et al.
Zollinger-Ellison syndrome.
,
1973,
Gastroenterology.
[7]
E. Emery.
Progress in Gastroenterology in 1936 and 1937
,
1938
.
[8]
K. Buchanan.
Gut hormones and gut endocrine tumour syndromes.
,
1980,
British journal of hospital medicine.